ArticleBMJ paediatrics open2026
Adverse drug events from paediatric use of extemporaneously compounded medicines in community pharmacy settings: a scoping review.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtemporaneously compounded medicines are widely used in paediatric patients. However, the associated extent and nature of adverse drug events from these products remained unclear.
aimsTo summarise the characteristics of adverse drug events reported from the use of compounded medicines in children and determine the types of adverse drug events, medications most frequently involved, and reasons for medication errors.
methodsA search was performed in Medline via Ovid, CINAHL, Embase, Scopus and the ISMP Canada Safety Bulletins to identify studies that described adverse drug events associated with community pharmacy compounded medicines. There were no restrictions based on country or publication date. Two authors independently screened titles, abstracts and full texts of studies of the studies found and extracted data with a standardised extraction table. Information extracted included study characteristics, details regarding the compounded medicine and clinical characteristics.
resultsWe identified 37 cases across 25 studies. There were 31 cases of compounding errors, 5 cases of administration errors and 1 case of dispensing error. The most common compounding error types were incorrect concentration in the formulation, substitution or addition of an active ingredient that was not prescribed. The most commonly reported medicines were clonidine (n=7) and flecainide (n=5). The median age of children involved was 2 years (IQR 0.9-5.5 years). Two deaths were reported, following exposures to baclofen and tacrolimus.
conclusionsThis review highlights the importance of thoroughly verifying active ingredients and their concentrations when compounding paediatric formulations in community pharmacies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.